Puromycin 2HCl

For research use only.

Catalog No.S7417 Synonyms: CL13900

65 publications

CAS No. 58-58-2

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

Selleck's Puromycin 2HCl has been cited by 65 publications

Cell, 2018, 174(6):1477-1491

PubMed: 30146158 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab034

PubMed: 33503260 ( click the link to review the publication )

Theranostics, 2021, 11(6):2966-2986

PubMed: 33456583 ( click the link to review the publication )

Autophagy, 2021, 1-17

PubMed: 33752561 ( click the link to review the publication )

Mol Ther Oncolytics, 2021, 20:583-595

PubMed: 33768140 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.12917

PubMed: 33528867 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):6

PubMed: 33423038 ( click the link to review the publication )

Front Cell Infect Microbiol, 2021, 11:627798

PubMed: 33718275 ( click the link to review the publication )

Biology (Basel), 2021, 10(3)234

PubMed: 33803505 ( click the link to review the publication )

Ann Transl Med, 2021, 9(2):104

PubMed: 33569406 ( click the link to review the publication )

Cell Death Dis, 2021, 12(2):147

PubMed: 33542209 ( click the link to review the publication )

Cell Death Dis, 2021, 12(2):220

PubMed: 33637706 ( click the link to review the publication )

Genome Biol, 2020, 21(1):269

PubMed: 33143730 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Cell Rep, 2020, 30(2):497-509

PubMed: 31940492 ( click the link to review the publication )

Oncogene, 2020, 39(21):4212-4226

PubMed: 32251364 ( click the link to review the publication )

Stem Cell Res, 2020, 49:102052

PubMed: 33130469 ( click the link to review the publication )

Cancer Lett, 2020, 469:380-389

PubMed: 31730901 ( click the link to review the publication )

Cancers (Basel), 2020, 20;12(2) pii: E493

PubMed: 32093281 ( click the link to review the publication )

Cancers (Basel), 2020, 23;12(3):758

PubMed: 32210086 ( click the link to review the publication )

Oncogenesis, 2020, 29;9(4):42

PubMed: 32350243 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(7):4223-4232

PubMed: 32105413 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):2847-2856

PubMed: 31778016 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:9372961

PubMed: 32908925 ( click the link to review the publication )
Int J Genomics, 2020, 2020:3750673

PubMed: 32509843 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11507

PubMed: 33245175 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):365

PubMed: 33133265 ( click the link to review the publication )

Pathogens, 2020, 9(6):443

PubMed: 32512928 ( click the link to review the publication )

Theranostics, 2020, 10(17):7906-7920

PubMed: 32685028 ( click the link to review the publication )

Exp Cell Res, 2020, 389(1):111894

PubMed: 32035950 ( click the link to review the publication )

J Craniomaxillofac Surg, 2020, 48(1):105-110

PubMed: 31884029 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:1413-1419

PubMed: 32110040 ( click the link to review the publication )

J Med Genet, 2020, jmedgenet-2019-106706

PubMed: 32737136 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:6539-6551

PubMed: 32753892 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3461-3475

PubMed: 32774712 ( click the link to review the publication )

J Clin Invest, 2019, 129(6):2333-2350

PubMed: 31063987 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5792

PubMed: 31857589 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1311-1322.e5

PubMed: 31665642 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0402-x

PubMed: 31406304 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):151

PubMed: 31672157 ( click the link to review the publication )

Oncogene, 2019, 38(2):180-193

PubMed: 30093630 ( click the link to review the publication )

PLoS Pathog, 2019, 15(6):e1007795

PubMed: 31170267 ( click the link to review the publication )

Cells, 2019, 8(11)E1335

PubMed: 31671755 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2019, 14:47-55

PubMed: 31309127 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(7):4545-4558

PubMed: 31062473 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)E4852

PubMed: 31574902 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):772-782

PubMed: 30429217 ( click the link to review the publication )

Exp Cell Res, 2019, 376(2):105-113

PubMed: 30772381 ( click the link to review the publication )
Exp Cell Res, 2019, 10.1016/j.yexcr.2019.06.006

PubMed: 31194977 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2969-2975

PubMed: 30867731 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):4124-4135

PubMed: 30783677 ( click the link to review the publication )

Front Oncol, 2019, 9:80

PubMed: 30873379 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):65

PubMed: 30286765 ( click the link to review the publication )

Mol Med Rep, 2018, 17(4):6116-6121

PubMed: 29436634 ( click the link to review the publication )

Theranostics, 2018, 8(15):4050-4061

PubMed: 30128035 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201701351

PubMed: 29906248 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(5 Pt A):1754-1769

PubMed: 29510196 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(2):341-349

PubMed: 29572031 ( click the link to review the publication )

Lab Invest, 2018, 98(12):1627-1641

PubMed: 30089852 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(5)

PubMed: 29786666 ( click the link to review the publication )

Nat Commun, 2017, 8(1):244

PubMed: 28811474 ( click the link to review the publication )

Cell Death Dis, 2017, 8(9):e3048

PubMed: 28906492 ( click the link to review the publication )

Oncotarget, 2017, 8(14):23401-23413

PubMed: 28423580 ( click the link to review the publication )

Oncotarget, 2017, 8(17):28865-28879

PubMed: 28427200 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3986-3994

PubMed: 27725879 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

In vitro

The antibiotic puromycin is produced by the actinoniycete, Streptornyces alboniger, and has been used as a tool for studying protein synthesis in a number of systems. ^[1] Puromycin can be used for the selection of recombinant cells from noncultured cells. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
K562	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mmm0O\|IhcA>?	NH7TcWtIem:5dHigbY5pcWKrdHnvckBw\iCmb4jvdpVjcWOrbj3y[ZNqe3SjboSgbJVu[W5iS{W2NkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxRTJ4LkizJO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh\|MUOzNFc9N2F-
HepG2	NFfhXmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXK3NkBp	M3PyV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4zOyEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh\|MUOzNFc9N2F-
K562	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWW3NkBp	NXL5Tm1PT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOjJizszNMi=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDNzM{OwO{c,OTh\|MUOzNFc9N2F-
HepG2	M{f3T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MVG3NkBp	NGDrOoJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOjFizszNMi=>	MkexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MUK5PFQoRjF6NUGyPVg1RC:jPh?=
Huh7	M3j6TmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoHnUm9XSVKWSWO6JGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIhmeGG2b3PlcIx2dGG{IHPhdoNqdm:vYTDj[YxtKGyrbnWgLGh2cDdrLDDDR\|UxRTZwNkOg{txONg>?	M1;MT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUe5O\|g{Lz5zOEW3PVc5OzxxYU6=
HEK239	M4L4RWN6fG:2b4jpZ4l1gSCjc4PhfS=>	MUO3NkBp	NFmyXFFEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyN\|kh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1ieiCkbIXlJIF{e2G7LDDJR\|UxRTBwNEKg{txONg>?	MljVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwOlAoRjJyNUW4NFYxRC:jPh?=
J774A1	NFHmZohEgXSxdH;4bYNqfHliYYPzZZk>		NUHsWIdiS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhUjd5NFGxJINmdGy\|IHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2xNEDPxE1w	NXPMT4hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|Q3OzZpPkKyPVM1PjN4PD;hQi=>
KB3-1	M1[yXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlTtO\|IhcHK\|	NXrKVmFPT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU0J\|LUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkGg{txONg>?	NHHTV3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|MxPyd-MUizNVM{ODd:L3G+
HepG2/Dox	NFG3XplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NGLuZZM4OiCqcoO=	NWnYOmF[T3Kxd4ToJIlvcGmkaYTpc44hd2ZibYXseIllenWpIILld4l{fGGwdDDoeY1idiCKZYDHNk9Fd3hiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFIxNjJizszNMi=>	NV33V\|ZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NVI6QDRpPkG4OVEzQTh2PD;hQi=>
HEK293	MnezR5l1d3SxeHnjbZR6KGG\|c3H5	MYG3NkBpenN?	MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdi2kYYPl[EBxdGG2ZTDy[YFl\XJiYX7hcJl{cXNuIFnDOVAhRSByLkO2NUDPxE1w	NHe4PGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[1NVU{Pyd-Mk[2OVE2Ozd:L3G+
HEK293	Mn3YR5l1d3SxeHnjbZR6KGG\|c3H5	MYS3NkBpenN?	MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuN\|UxPSEQvF2u	M4XBRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|Y{Lz5{N{C2NFc3OzxxYU6=
A549	Mn3KR5l1d3SxeHnjbZR6KGG\|c3H5		MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE43KM7:TT6=	M17leFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlE1Lz5{N{C4PVIyPDxxYU6=
PC3	MofFR5l1d3SxeHnjbZR6KGG\|c3H5		MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOsJGlEPTBiPTCwMlch\|ryPLh?=	M{W2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi5NlE1Lz5{N{C4PVIyPDxxYU6=
HEK293	NEfiN3pEgXSxdH;4bYNqfHliYYPzZZk>		M3zCd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODByM{Wg{txONg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJzMkC3NEc,Ojd{MUKwO\|A9N2F-
HEK293	NYSxOnpWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFPqeHk4OiCqcoO=	MVrHdo94fGhiaX7obYJqfGmxbjDv[kBJTUt{OUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFC{ZYP0c2JtfWVic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5\|NjFOwG0v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDByMUC2O{c,OjhyMEGwOlc9N2F-
HEK293	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{LNWmdzd3e2aDDpcohq[mm2aX;uJI9nKEiHS{K5N{Bk\WyuczygTWM2OCB;IECuN\|k6KM7:TT6=	MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MECyN\|EoRjJ6NECwNlMyRC:jPh?=
SU-DHL10	MnHxR5l1d3SxeHnjbZR6KGG\|c3H5	NV3DZnZzPzJiaILz	M{PQNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTEGwJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCFQ{WwJF0hOC5zMTFOwG0v	NWfI[451RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlMyODNpPkK4OVI{OTB\|PD;hQi=>
MIAPaCa2	NHjKdYlEgXSxdH;4bYNqfHliYYPzZZk>	NFf5ZXo4OiCqcoO=	NGTuUZpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDhd5NigSxiQ1O1NEA:KDBwMjFOwG0v	NVLzZpQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlMyODNpPkK4OVI{OTB\|PD;hQi=>
MDA-MB-231	NIjJR5ZEgXSxdH;4bYNqfHliYYPzZZk>	M1H6eVczKGi{cx?=	NUH1dnQ1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW\|Y3XueEBie3OjeTygR2M2OCB;IECuOFgh\|ryPLh?=	MlfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkOxNFMoRjJ6NUKzNVA{RC:jPh?=
HEK293	MorPR5l1d3SxeHnjbZR6KGG\|c3H5	M1O3VlczKGi{cx?=	NGnX[mJEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSByLkS2JO69VS5?	NVXwXYFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O\|Q1OjdpPkK4O\|c1PDJ5PD;hQi=>
HL60	MljvRY51cXCjcnHzbZRq[yCjc4PhfS=>	NH7VWHM4OiCqcoO=	M4LDXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDFR\|UxKD1iMD6wOVUh\|ryPLh?=	NFHOU3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwN\|A1Pyd-Mki4NFMxPDd:L3G+
MOLT4	M{T5SmFvfGmyYYLhd4l1cWNiYYPzZZk>	MVS3NkBpenN?	M33l[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNVch\|ryPLh?=	NFzLfXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiwN\|A1Pyd-Mki4NFMxPDd:L3G+
Vero	NGe5W3BEgXSxdH;4bYNqfHliYYPzZZk>	NVzV[INsPzJiaILz	MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBC\nKrY3HuJIdz\WWwIH3vcotmgSCYZYLvJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDJwODFOwG0v	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhyM{C0O{c,Ojh6MEOwOFc9N2F-
HEK293	NUP4UJdSS3m2b4TvfIlkcXS7IHHzd4F6	M2qxXVczKGi{cx?=	M4rvUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nlicnXzZZp2emmwIHT5[UBj[XOnZDDhd5NigSxiSVO1NEA:KDBwNEWg{txONg>?	MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{M{[0PVIoRjJ7MkO2OFkzRC:jPh?=
HEK293T	MnvuR5l1d3SxeHnjbZR6KGG\|c3H5	NGXkNoM4OiCqcoO=	M4\vN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7M2SgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hemWjZ3XueEBj[XOnZDDseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGNEPTBiPTCwMlQzKM7:TT6=	M{XzTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HCT8	MoHXRY51cXCjcnHzbZRq[yCjc4PhfS=>	MofoOFghcHK\|	NI\3PVBCdnSrcHHyZZNqfGmlIHHjeIl3cXS7IHHnZYlve3RiQ4L5dJRwe3CxcnnkbZVuKHCjco\1cUBDT0ZiaX7m[YN1\WRiaX6gbJVu[W5iSFPUPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCISWTDM2RCWElic4ThbY5qdmdiYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC53NTFOwG0v	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4OUW3OUc,Ojl2Nkm1O\|U9N2F-
HCT8	MXvBcpRqeGG{YYPpeIlkKGG\|c3H5	NWq5cJNmPDhiaILz	MYnBcpRqeGG{YYPpeIlkKGGldHn2bZR6KGGpYXnud5QhS3K7cITvd5BwemmmaYXtJJBien[3bTDTVGwhcW6oZXP0[YQhcW5iaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBHUVSFL1TBVGkhe3SjaX7pcoch[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBGSzVyIE2gNE43KM7:TT6=	NH;HUm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2PVU4PSd-Mkm0Olk2PzV:L3G+
HepG2	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=	M3ryeVczKGi{cx?=	M2G3U2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJJJm[WenboSgZoF{\WRibIXtbY5me2OnbnPlJIF{e2G7LDDDR\|UxKD1iMD64N{DPxE1w	MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nkm1O\|UoRjJ7NE[5OVc2RC:jPh?=
HCT8	MmX3R5l1d3SxeHnjbZR6KGG\|c3H5		M1HHfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDhiY3XscJMtKEWFNUCgQUA3NjFizszNMi=>	M{OxcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[5OVc2Lz5{OUS2PVU4PTxxYU6=
HEK293	NXe5XFFVS3m2b4TvfIlkcXS7IHHzd4F6	NYXGUFJLPzJiaILz	M4rrWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuOFYh\|ryPLh?=	NHHXW\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN\|YyOSd-Mkm1N\|M3OTF:L3G+
HEK293	M2j4[GN6fG:2b4jpZ4l1gSCjc4PhfS=>	NHPhVpQ4OiCqcoO=	NVLIWmNCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEWNMkmzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC{ZYPhfpVzcW5iZInlJIJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuOEDPxE1w	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl4OUK2Nkc,Ojl7NkmyOlI9N2F-
A549	M3y4e2N6fG:2b4jpZ4l1gSCjc4PhfS=>	NYnQTo1xPDhiaILz	NGjaV\|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{whUUN3MDC9JFAvOyEQvF2u	M3nFSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEG4O\|Y{Lz5\|MESxPFc3OzxxYU6=
PC3	M4XsO2N6fG:2b4jpZ4l1gSCjc4PhfS=>	MUC0PEBpenN?	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|LDDJR\|UxKD1iMD6zJO69VS5?	NI\4[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MESxPFc3Oyd-M{C0NVg4PjN:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / CDK4; PubMed: 31022952 Cancers (Basel) (C) Effect of puromycin on cyclin D1 and CDK4 in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4 and β actin. (D) Effect of puromycin on cyclin D1 and CDK4 in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of cyclin D1, CDK4, and β-actin. PARP / Bcl-xL / Bcl-2 / p-Akt / Akt; PubMed: 31022952 Cancers (Basel) (E) Effect of puromycin on Poly (ADP-ribose) polymerase (PARP), Bcl-xL, Bcl-2, AKT, and p-AKT (v-akt murine thymoma viral oncogene homolog) in a concentration-dependent manner in HCT116 and H1299 cells. Cells were treated with puromycin (0.25 or 0.5 μg/mL) for 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin. (F) Effect of puromycin on PARP, Bcl-xL, Bcl-2, AKT, and p-AKT in a time-dependent manner in HCT116 and H1299 cells. Cells were treated with 0.5 μg/mL of puromycin for 3, 6, 12 or 24 h and subjected to Western blotting with antibodies of PARP, Bcl-xL, Bcl-2, p-AKT, AKT, and β-actin. p53 / p21 / c-Myc; PubMed: 31022952 Cancers (Basel) Effect of puromycin on p53, p21, and c-Myc in a concentration and time-dependent manner in HCT116 cells. HCT116 cells were exposed to various concentrations of puromycin (0.25 or 0.5 μg/mL) for 24 h and then subjected to Western blotting with antibodies of p53, p21, and c-Myc. Also, HCT116 cells were treated with 0.5 μg/mL puromycin for 6, 12, or 24 h and subjected to Western blotting.	31022952
Growth inhibition assay	Cell viability; PubMed: 31022952 Cancers (Basel) Cytotoxicity of puromycin in HCT116, SW620, HCT15, and H1299 cells in a concentration-dependent manner by 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Data represent means ± SD. , p < 0.05, , p < 0.01, **, p< 0.001 vs. untreated control.	31022952

Protocol

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (183.67 mM)
	Water	100 mg/mL warmed (183.67 mM)
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Puromycin 2HCl SDF

Molecular Weight	544.43
Formula	C₂₂H₂₉N₇O₅.2HCl
CAS No.	58-58-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CL13900
Smiles	CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)NC(=O)C(CC4=CC=C(C=C4)OC)N)O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Related Antineoplastic and Immunosuppressive Antibiotics Products

Mycophenolic acid

Mycophenolic acid (Mycophenolate, RS-61443) is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.
Neomycin sulfate

Neomycin sulfate is an aminoglycoside antibiotic, used to treat bacteria infections.
Tetracycline HCl

Tetracycline HCl (NCI-c55561) is a hydrochloride salt of tetracycline that is a broad-spectrum polyketide antibiotic.
Hygromycin B

Hygromycin B (Hygrovetine), a selective antibiotic that is effective on most bacteria, fungi and higher eukaryotes, inhibits protein synthesis by interfering with translocation and causing mistranslation at the 70S ribosome.
Geneticin (G418 Sulfate)

Geneticin (G418 Sulfate), an aminoglycoside antibiotic, is an elongation inhibitor of 80 S ribosomes that blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells.
Blasticidin S HCl

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

Choose Your Country or Region

By Signaling Pathways

By product type

Puromycin 2HCl